{
    "id": 31969,
    "fullName": "ALK L1152V",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ALK L1152V lies within the protein kinase domain of the Alk protein (UniProt.org). L1152P is associated with decreased ALK inhibitor sensitivity in the context of an ALK fusion in culture (PMID: 22034911), but has not been biochemically characterized and therefore, its effect on Alk protein function is unknown (PubMed, Jan 2020).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 11557,
                    "pubMedId": 22034911,
                    "title": "Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22034911"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 238,
        "geneSymbol": "ALK",
        "terms": [
            "ALK",
            "CD246",
            "NBLST3"
        ]
    },
    "variant": "L1152V",
    "createDate": "01/06/2020",
    "updateDate": "01/06/2020",
    "referenceTranscriptCoordinates": {
        "id": 186293,
        "transcript": "NM_004304",
        "gDna": "chr2:g.29222405G>C",
        "cDna": "c.3454C>G",
        "protein": "p.L1152V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19688,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, Ensartinib (X-396) treatment resulted in an objective response in 50% (2/4, all partial responses) and stable disease in 25% (1/4) of patients with ALK-positive non-small cell lung cancer harboring ALK L1152R (n=3) or L1152V (n=1) (PMID: 31628085; NCT0321569).",
            "molecularProfile": {
                "id": 34421,
                "profileName": "ALK L1152V ALK pos"
            },
            "therapy": {
                "id": 961,
                "therapyName": "Ensartinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16908,
                    "pubMedId": 31628085,
                    "title": "Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31628085"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 34420,
            "profileName": "ALK L1152V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34421,
            "profileName": "ALK L1152V ALK pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 186293,
            "transcript": "NM_004304",
            "gDna": "chr2:g.29222405G>C",
            "cDna": "c.3454C>G",
            "protein": "p.L1152V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}